A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 319 participants.
Also called NCT05628311
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 319 participants
- Registry
-
NCT05628311
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05628311. Randomized; double masking; primary purpose treatment. Start 2023-01-06 (actual); primary completion 2023-10-25 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
- Condition
- Type 2 Diabetes
- Intervention (Other)
- placebo
- Intervention (Drug)
- IBI362
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Record details
- Record id
cardio:ct-nct05628311- Content hash
e008470e4b0ed0faba38f60e3303682f2887f12a368b9615618cafa80c83166d